Why Structure Therapeutics Stock Doubled and Then Some on Monday
Key Points
Shareholders were extremely pleased by the biotech's latest news from the lab.
This concerned its pipeline weight-loss drug aleniglipron.
- 10 stocks we like better than Structure Therapeutics ›
Monday was quite the day for biotech companies developing the next generation of obesity drugs. One of them, Structure Therapeutics (NASDAQ: GPCR), skyrocketed almost 103% higher in price that day on some highly promising data produced by its weight-loss candidate medication.
A successful study
Structure, which concentrates on metabolic diseases with a particular focus on obesity, unveiled the topline data for its GLP-1 drug aleniglipron. The weight-loss treatment was put through its paces in a phase 2b study.
Where to invest $1,000 right now? Our analyst team just revealed what they believe are the 10 best stocks to buy right now. Continue »
Image source: Getty Images.
Over the course of the 36-week study, Structure reported that the oral medication resulted in a placebo-adjusted average weight reduction of over 11%. By the end of the study, slightly over 10% of the participants dropped out due to adverse events.
Generally, however, aleniglipron demonstrated tolerability essentially in line with other GLP-1 obesity treatments.
Structure stated that, based on the drug's performance, the company aims to advance it into phase 3 clinical trials.
The most competitive segment
In the press release detailing the results, Structure quoted CEO Raymond Stevens as saying that aleniglipron "is differentiated and delivered clinically meaningful, competitive and dose-dependent weight loss with a safety profile appropriate for chronic use in a disease that impacts millions of people."
If it continues to perform as efficaciously and eventually wins regulatory approval, the treatment could be very competitive in a weight-loss segment that is becoming increasingly busy seemingly every day. The company will have its work cut out for it, though, as tough competitors already have obesity products on the market, and others are feverishly working to develop next-level ones.
In fact, a peer biotech, Wave Life Sciences, also announced encouraging results on Monday from a recent clinical trial of its own developmental weight-loss drug.
Should you invest $1,000 in Structure Therapeutics right now?
Before you buy stock in Structure Therapeutics, consider this:
The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Structure Therapeutics wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years.
Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you’d have $540,587!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you’d have $1,118,210!*
Now, it’s worth noting Stock Advisor’s total average return is 991% — a market-crushing outperformance compared to 195% for the S&P 500. Don’t miss out on the latest top 10 list, available when you join Stock Advisor.
See the 10 stocks »
*Stock Advisor returns as of December 8, 2025
Eric Volkman has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.
Recommended Articles
